By

Lundbeckfonden
New Haven, CT, July 19, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritic conditions, announced today that it has named Yann Mazabraud as its Chief Commercial Officer and Head of International. Mr. Mazabraud will join Trevi’s senior management team and be responsible for overseeing Trevi’s commercial strategy and international operations....
Lund, Sweden, 18:30 CET, 18 July 2018 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone voids, announces that Michael Diefenbeck MD PhD, BONESUPPORT’s Chief Medical Officer, has been appointed to assume a broader role as Head of R&D, Medical and Clinical Affairs. Emil Billbäck, CEO of BONESUPPORT, commented: “We are pleased...
Cambridge, UK and Indianapolis, US – 9 July 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH) provides an unaudited operating update for the first half 2018 (six months ended 30 June 2018). Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialisation of new nausea &...
Edinburgh – July 9th, 2018 – DYSIS Medical Ltd, the developer of the innovative DYSIS Ultra colposcope used in cervical cancer screening, announces today the completion of an £18 million ($25 million) investment. Within the past year, DYSIS Medical has made significant strides and achieved key milestones including the launch of the latest generation device (DYSIS...
Lund, Sweden, 18:00 CET, July 4 2018 – BONESUPPORT™ an emerging leader in Orthobiologics for the management of bone voids, announces changes in its leadership team that are expected to take place at the end of 2018, when Håkan Johansson will replace Björn Westberg as the company’s CFO. Håkan Johansson is an experienced financial executive...
Cambridge, UK and Indianapolis, US – 2 July 2018: Acacia Pharma Group plc (“Acacia Pharma”, the “Company” or the “Group”), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea & vomiting treatments for surgical and cancer patients, has secured a credit facility of up to $30 million with Hercules Technology...
Lund, Sweden, 18:00 CET 29 June 2018 – During June, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 29 June 2018, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 50,812,116. For more information contact: Emil Billbäck, CEO...
Lund, Sweden, 08:30 CET, 21 June 2018 – BONESUPPORT™ an emerging leader in Orthobiologics for the management of bone voids, today provides an update on the US orders of CERAMENT BVF. Following BONESUPPORT’s decision to set up its own distribution network in the US and terminate its current exclusive distribution agreement, as announced 17 May...
The University of Copenhagen and Lundbeck Foundation are establishing a new research centre to map the interaction between human DNA and diseases through the ages. The centre is the first of its kind in the world. It will focus on neurological diseases and psychiatric disorders, and the data will come from bones and teeth. The...
SAN DIEGO – June 7, 2018 – Amplyx Pharmaceuticals, a company developing first-in-class products for life-threatening infections, today announced that Amplyx and its collaborators will be participating in and presenting at two scientific conferences in the upcoming weeks. Presentations will focus on the company’s lead drug candidate, APX001, which is currently in development for the...
1 2 3 10

News

How it can help to give an electric shock  
17. July 2018
1,000 old skeletons to provide new knowledge about brain disorders
17. June 2018
Lundbeck Foundation’s magazine out now
1. June 2018

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge